Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $27.9 million.

  • Fennec Pharmaceuticals' Shares Outstanding (Diluted Average) fell 44.98% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.9 million, marking a year-over-year decrease of 44.98%. This contributed to the annual value of $27.3 million for FY2024, which is 270.94% up from last year.
  • Fennec Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $27.9 million in Q3 2025, which was down 44.98% from $27.7 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $31.1 million during Q1 2024, with a 5-year trough of $26.0 million in Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $26.6 million (2023), whereas its average is $27.1 million.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Shares Outstanding (Diluted Average) soared by 3069.46% in 2021, and later plummeted by 1129.91% in 2025.
  • Fennec Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $26.0 million in 2021, then grew by 1.03% to $26.3 million in 2022, then grew by 1.14% to $26.6 million in 2023, then rose by 2.71% to $27.3 million in 2024, then increased by 2.18% to $27.9 million in 2025.
  • Its last three reported values are $27.9 million in Q3 2025, $27.7 million for Q2 2025, and $27.6 million during Q1 2025.